ADMA Biologics: MACD Death Cross and KDJ Death Cross Triggered on 15min Chart.

ADMA Biologics's 15-minute chart has triggered a MACD Death Cross and a KDJ Death Cross at 07/21/2025 15:00, indicating that the stock price has the potential to continue declining. The momentum of the stock price is shifting towards the downside, and there is a potential for further decreases in the stock's value.

ADMA Biologics (ADMA) has experienced a significant decline in its stock price, with the latest trading day closing at $17.98, representing a 3.75% drop from the previous session. This decline follows a broader market trend where the S&P 500 lost 0.4%, the Dow fell by 0.98%, and the Nasdaq gained 0.18%. Over the past month, ADMA's shares have depreciated by 8.43%, underperforming the Medical sector's loss of 1.56% and the S&P 500's gain of 4.97% [1].

Investors and analysts are closely monitoring ADMA's upcoming earnings disclosure, which is anticipated to report an EPS of $0.14, marking a 7.69% increase compared to the same quarter of the previous year. The consensus estimate forecasts revenue to be $121.1 million, indicating a 12.98% growth compared to the corresponding quarter of the prior year. For the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.61 per share and a revenue of $505.8 million, indicating changes of +24.49% and +18.61%, respectively, from the former year [2].

The stock is currently trading at a Forward P/E ratio of 30.62, which is a premium compared to its industry average Forward P/E of 17.7. The Medical - Biomedical and Genetics industry, which ADMA is part of, has a Zacks Industry Rank of 77, placing it in the top 32% of all 250+ industries [2].

Adding to the bearish sentiment, ADMA Biologics has triggered a MACD Death Cross and a KDJ Death Cross on July 21, 2025, at 15:00, indicating a potential continuation of the downward trend in the stock price. This suggests that the momentum of the stock is shifting towards the downside, and there is a potential for further decreases in the stock's value [3].

Investors should closely monitor ADMA Biologics' performance and any recent adjustments to analyst estimates, as these changes can provide insights into the company's near-term business trends and future stock price movements. The Zacks Rank, which considers these estimate changes, currently has ADMA Biologics ranked as a #4 (Sell) [2].

References:
[1] https://finance.yahoo.com/news/adma-biologics-adma-declines-more-215003315.html
[2] https://www.nasdaq.com/articles/adma-biologics-adma-declines-more-market-some-information-investors
[3] https://ng.investing.com/news/stock-market-news/palantir-eli-lilly-lead-thursdays-market-cap-stock-movers-93CH-1909464